Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/wnl.60.1.152 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Predicting successful outcomes of gastric peroral endoscopic myotomy (G-POEM) is essential for identifying patients who are most likely to benefit from the procedure. This study aimed to evaluate the utility of the balloon dilation test (BDT) in optimizing patient selection for G-POEM.
Methods: A retrospective study was conducted from February 2021 to December 2023, including patients with refractory gastroparesis unresponsive to conventional medical treatments.
Quality of Life in Adults with Atopic Dermatitis in Relation to Disease Severity: Nationwide Data in Japan.
Dermatol Ther (Heidelb)
January 2025
Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-ku, Tokyo, 108-8241, Japan.
Introduction: The impact of atopic dermatitis (AD) on daily life and different levels of quality of life (QOL) according to AD severity has not been fully elucidated. This study aimed to assess QOL in relation to the AD severity in Japan.
Methods: This observational study used anonymized data of health insurance association members and their families registered to a mobile health app.
Self-Guided vs Clinician-Guided Online Cognitive Behavioral Therapy for Atopic Dermatitis: A Randomized Clinical Trial.
JAMA Dermatol
December 2024
Department of Clinical Neuroscience, Division of Psychology, Karolinska Institutet, Stockholm, Sweden.
Importance: Clinician-guided online self-help based on cognitive behavioral therapy (CBT) has been shown to be effective at decreasing symptom severity for people with atopic dermatitis (AD). A brief online self-guided CBT intervention could be more cost-effective and allow for easy implementation and broader outreach compared with more comprehensive clinician-guided interventions.
Objective: To investigate whether a brief online self-guided CBT intervention is noninferior to a comprehensive online clinician-guided CBT treatment.
The assessment of dupilumab in children with moderate-to-severe asthma and comorbid type 2 inflammatory diseases.
BMC Pulm Med
December 2024
Department of respiratory, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Background: Dupilumab inhibiting the signaling of interleukin(IL)-4 and IL-13 was recommended for the treatment of severe asthma in children ≥ 6 years old according to the Global Initiative for Asthma (GINA,2024).This study aimed to analyse the efficacy and safety of dupilumab in paediatric patients with moderate-to-severe asthma and comorbid type 2 inflammatory disease in a real-world population.
Methods: We evaluated the medical records of paediatric patients with moderate-to-severe asthma and comorbid type 2 inflammatory diseases, such as atopic dermatitis (AD) and allergic rhinitis (AR), receiving dupilumab treatment.
Article Synopsis
- Atopic dermatitis (AD) significantly affects patients' quality of life, causing itching, skin pain, and sleep disturbances; ruxolitinib cream has shown effectiveness in treating these symptoms in adults and adolescents through two phase III clinical trials.
- In the TRuE-AD studies, patients applied different strengths of ruxolitinib cream or a vehicle cream, with results indicating that those using ruxolitinib experienced quick relief from symptoms like skin pain and sleep issues within hours or weeks of application.
- Analysis of patient-reported outcomes revealed notable improvements in overall quality of life and symptom burden after two weeks of using ruxolitinib cream compared to the vehicle, with sustained benefits observed throughout the study periods.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!